Concepedia

Author

Mengxuan Zuo

Sun Yat-sen UniversityORCID

Also Known As

Meng-Xuan Zuo, Meng-xuan Zuo, Mengxuan Zuo, Meng‐Xuan Zuo, Meng‐xuan Zuo

49

Publications

497

Citations

12

H-Index

20

Concepts

All Affiliations

Sun Yat-sen UniversitySun Yat-sen University Cancer CenterState Key Laboratory of Oncology in South ChinaChinese Academy of Medical Sciences & Peking Union Medical CollegePeking Union Medical College Hospital
MZ

About

Mengxuan Zuo is an author at Sun Yat-sen University specializing in immunology, immunotherapy, and medicine.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

2

2

24

2

Immunology

2

2

24

3

Pathology

2

2

24

4

Health Sciences

1

1

14

5

Hepatology

1

1

14

Mengxuan Zuo

×

16

Publications

371

Citations

12

H-Index

YearCitations

Camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and hepatic artery infusion chemotherapy for hepatocellular carcinoma in Barcelona Clinic Liver Cancer stage C (TRIPLET): a phase II study

Tianqi Zhang, Zhijun Geng, Mengxuan Zuo,

Signal Transduction and Targeted Therapy

2023

107

PD‐1 expression on the surface of peripheral blood CD4<sup>+</sup> T cell and its association with the prognosis of patients with diffuse large B‐cell lymphoma

Wei Zhang, Jie‐Fei Bai, Mengxuan Zuo,

Cancer Medicine

2016

36

A multitask deep learning radiomics model for predicting the macrotrabecular-massive subtype and prognosis of hepatocellular carcinoma after hepatic arterial infusion chemotherapy

Xuelei He, Kai Li, Ran Wei,

La radiologia medica

2023

33

Infiltrative Hepatocellular Carcinoma: Transcatheter Arterial Chemoembolization Versus Hepatic Arterial Infusion Chemotherapy

Chao An, Mengxuan Zuo, Wang Li,

Frontiers in Oncology

2021

32

Microwave ablation versus liver resection for primary intrahepatic cholangiocarcinoma within Milan criteria: a long-term multicenter cohort study

Chuan Pang, Jianming Li, Jianping Dou,

EClinicalMedicine

2024

23

Postprogression treatment of lenvatinib plus PD‐1 inhibitor in advanced hepatocellular carcinoma refractory to hepatic arterial infusion chemotherapy

Chao An, Yan Fu, Wang Li,

Cancer

2023

18

Four types of tumor progression after microwave ablation of single hepatocellular carcinoma of ≤5 cm: incidence, risk factors and clinical significance

Zhimei Huang, Zhixing Guo, Jiayan Ni,

International Journal of Hyperthermia

2021

14

TIPS plus sequential systemic therapy of advanced HCC patients with tumour thrombus-related symptomatic portal hypertension

Zhenkang Qiu, Guobao Wang, Huzheng Yan,

European Radiology

2022

14

Hepatic artery infusion chemotherapy (HAIC) combined with apatinib and camrelizumab for hepatocellular carcinoma (HCC) in BCLC stage c: A prospective, single-arm, phase II trial (TRIPLET study).

Yangkui Gu, Tianqi Zhang, Mengxuan Zuo,

Journal of Clinical Oncology

2022

14

Hepatic arterial chemotherapy infusion combined with tyrosine kinase inhibitors and PD-1 inhibitors for advanced hepatocellular carcinoma with high risk: a propensity score matching study

Mengxuan Zuo, Guanglei Zheng, Yuzhe Cao,

International Journal of Surgery

2024

13

Page 1